The Phase 2 schizophrenia trial for BRIUMVI (ublituximab) represents a potential option on an addressable market 20-30 times larger than the MS indication — if the neuroinflammatory hypothesis holds, the commercial implications could drive a fundamental re-rating of TG Therapeutics' $8.49 billion valuation.
Key Highlights
- Massive Addressable Market: Schizophrenia affects approximately 1% of the global population — roughly 80 million people — compared to approximately 2.8 million relapsing MS patients globally where BRIUMVI is currently approved.
- Validated MS Safety Profile: BRIUMVI's established safety and tolerability data from the MS programme provides a valuable starting point for Phase 2 risk assessment in schizophrenia.
- Binary Option Value: A positive Phase 2 schizophrenia signal could dramatically re-rate TG Therapeutics toward large-cap biotech valuations; a negative signal would leave the MS franchise value intact.
Schizophrenia: The Commercial Opportunity If the Hypothesis Is Correct
Schizophrenia is one of the most commercially significant unmet medical needs in psychiatry. The disease affects approximately 1% of the global population — roughly 80 million people worldwide — and is characterised by positive symptoms (hallucinations, delusions, disorganised thinking), negative symptoms (flat affect, social withdrawal, reduced motivation), and cognitive impairment across attention, memory, and executive function domains.
Current treatment with second-generation antipsychotics controls positive symptoms in approximately 70% of patients but has minimal efficacy against negative symptoms and cognitive impairment — the dimensions of the disease that most severely impair functional recovery, employment, and quality of life. Additionally, 20-30% of patients do not achieve adequate symptom control with available antipsychotics, representing a large treatment-refractory population with no effective alternatives beyond clozapine, which carries significant side effect risks including agranulocytosis.
A B-cell depletion therapy that demonstrated efficacy in the neuroinflammatory subset of schizophrenia — a subset that may represent anywhere from a small fraction to a meaningful proportion of the overall population depending on how precisely autoimmune contributions to schizophrenia can be defined — would be commercially transformative. Even capturing 5% of the global schizophrenia patient population with a premium-priced biological therapy would represent a revenue opportunity several times larger than the entire MS market where BRIUMVI currently operates.
The Scientific Precedent: Autoimmune Encephalitis as the Proof of Concept
The strongest scientific argument for anti-CD20 therapy in schizophrenia comes from the well-documented phenomenon of autoimmune encephalitis — a group of neurological diseases caused by autoantibodies targeting neuronal surface receptors and proteins. The most common form, anti-NMDA receptor encephalitis caused by antibodies against the GluN1 subunit of the NMDA receptor, presents with an acute psychiatric syndrome characterised by psychosis, hallucinations, and catatonia that is clinically indistinguishable from schizophrenia.
The critical insight from autoimmune encephalitis research is that B-cell mediated autoantibody production can cause a psychotic syndrome that responds to immunotherapy — including rituximab (an anti-CD20 antibody) — rather than to antipsychotics alone. This proof-of-concept demonstrates that at least some psychotic syndromes are immune-mediated and responsive to B-cell depletion.
The question for the schizophrenia Phase 2 trial is whether the autoimmune mechanism documented in autoimmune encephalitis also contributes to a subset of patients classified as having chronic schizophrenia. Growing evidence from several research groups suggests that a proportion of schizophrenia patients have elevated autoantibody titres against neuronal surface proteins — though the biological significance and clinical representativeness of these findings remain actively debated in the scientific literature.
Phase 2 Design Considerations and Investment Implications
The success of TG Therapeutics' schizophrenia Phase 2 will depend critically on the trial's patient selection strategy. If the trial enrols a broad, unselected schizophrenia population, the proportion of patients with an underlying autoimmune mechanism may be insufficient to produce a detectable clinical signal — diluting the potential responder subset with non-responders who lack the immunological profile that would make them candidates for B-cell depletion therapy.
A better-designed study would enrich the patient population for individuals with evidence of immune dysregulation — whether through elevated inflammatory biomarkers, specific autoantibody titres, or genetic risk variants that co-localise with both schizophrenia and autoimmune disease susceptibility loci. This enrichment strategy would maximise the probability of observing a clinical signal in the study while providing mechanistic clarity about which patients are responding and why.
For TG Therapeutics investors, the schizophrenia Phase 2 represents a free embedded option within an MS commercial franchise that provides fundamental valuation support regardless of the schizophrenia trial outcome. If the Phase 2 succeeds, the valuation re-rating could be dramatic. If it fails, the MS business provides a durable commercial foundation. This asymmetric option structure — significant upside with limited incremental downside — explains the 4% positive market reaction to the Phase 2 enrollment initiation announcement.
Frequently Asked Questions
Disclaimer: This article is for informational and educational purposes only and does not constitute financial or investment advice. Readers should conduct their own due diligence before making investment decisions.






Please wait processing your request...